Secretory carcinomas of the breast are rare tumors with distinct histologic features, recurrent t(12;15)(p13;q25) translocation resulting in ETV6-NTRK3 gene fusion and indolent clinical behavior. Mammary analog secretory carcinomas arising in other sites are histopathologically similar to the breast tumors and also harbor ETV6-NTRK3 fusions. Breast secretory carcinomas are often triple (estrogen and progesterone receptor, HER2) negative with a basal-like immunophenotype. However, genomic studies are lacking, and whether these tumors share genetic features with other basal and/or triple negative breast cancers is unknown. Aside from shared ETV6-NTRK3 fusions, the genetic relatedness of secretory carcinomas arising in different sites is also uncertain. We immunoprofiled and sequenced 510 cancer-related genes in nine breast secretory carcinomas and six salivary gland mammary analog secretory carcinomas. Immunoprofiles of breast and salivary gland secretory carcinomas were similar. All the tumors showed strong diffuse MUC4 expression (n = 15), and SOX10 was positive in all nine breast and in five out of six salivary gland tumors. All breast secretory carcinomas were triple negative or weakly ER-positive, and all tumors at both the sites expressed CK5/6 and/or EGFR, consistent with a basal-like phenotype. Sequencing revealed classic ETV6-NTRK3 fusion genes in all cases, including in carcinoma in situ of one breast tumor. Translocations were reciprocal and balanced in six out of nine breast and three out of six salivary gland tumors and were complex in three others. In contrast to most breast basal carcinomas, the mutational burden of secretory carcinomas was very low, and no additional pathogenic aberrations were identified in genes typically mutated in breast cancer. Five (56%) breast and two (33%) salivary gland tumors had simple genomes without copy number changes; the remainder had very few changes, averaging 1.3 per tumor. The ETV6-NTRK3 derivative chromosome was duplicated in one breast and one salivary gland tumor, and was the only copy number change in the latter. The findings highlight breast secretory carcinoma as a subtype more closely related to mammary analog secretory carcinoma than to basal/triple negative breast cancers of no special type. Lack of pathogenic mutations in common cancer-related genes suggests that ETV6-NTRK3 alone may suffice to drive these tumors and likely helps explain their indolent behavior. Modern Pathology (2017Pathology ( ) 30, 1086Pathology ( -1099 doi:10.1038/modpathol.2017 published online 26 May 2017 Secretory carcinomas of the breast are a very rare special subtype of breast cancer, estimated to comprise approximately 0.15% of all breast carcinomas, with distinctive histopathologic features and favorable clinical behavior. 1-6 Initially described in children and adolescents, more recent studies indicate that secretory carcinomas are more common
in adults. 4, 5, 7, 8 The overall prognosis is favorable even in the presence of local lymph node metastasis, with only vanishingly rare distant metastases. Fiveand 10-year disease-related survival is 94% and 91%, respectively. 4, 8 Secretory carcinomas are prototypical of genotype-phenotype correlation among tumors, demonstrating characteristic histologic and immunohistochemical features and a recurrent t(12;15)(p13;q25) translocation that creates an ETV6-NTRK3 fusion gene, which is specific among breast tumors. 1,2,5,9,10 ETV6-NTRK3 encodes a chimeric tyrosine kinase that signals through Rasmitogen activated protein kinase and phosphatidyl inositol-3 kinase pathways to transform cells of multiple lineages. [11] [12] [13] [14] [15] [16] Morphologic features of breast secretory carcinomas are those of grade 1 or grade 2 tumors comprised of polygonal cells with eosinophilic or vacuolated cytoplasm and small, round to oval nuclei arranged in microcystic, solid, tubular, or papillary growth patterns and associated with periodic acid Schiff (PAS)-positive secretions. 1, 2, 5, 6, 17 High-grade tumors have only rarely been reported. 1 The tumor cells characteristically express S100 protein, mammaglobin, and STAT5a and are either triple (estrogen receptor [ER] , progesterone receptor [PR] , and HER2) negative or only weakly ER/PRpositive. 1, 2, [17] [18] [19] [20] Several studies have demonstrated a basal-like phenotype of secretory carcinomas by immunohistochemistry, including positivity for EGFR and the basal keratin CK5/6, in addition to the triple negative or weakly ER-positive status. 1, 17 However, the excellent prognosis and long-term outcome of patients with secretory carcinoma, even in the presence of axillary lymph node metastasis, is in stark contrast to the majority of triple negative or basal breast cancers, highlighting the heterogeneity of basal tumors and the need for comprehensive histopathologic evaluation. 4, 8, [21] [22] [23] Although large sequencing projects, including The Cancer Genome Atlas (TCGA) and the Molecular Taxonomy of Breast Cancer International Consortium (METABRIC), have interrogated the genomic landscape of breast cancers, these studies have focused on the overwhelming majority of invasive carcinomas of no special type and have generally not included special histologic subtypes. 21, 22, [24] [25] [26] [27] [28] [29] [30] [31] Indeed, aside from targeted studies of the ETV6-NTRK3 fusion and array comparative hybridization studies, the genomics of secretory carcinomas remain largely unexplored, and next-generation DNA sequencing studies of these rare tumors are lacking. 1, 2, 9, 17, 32, 33 Accordingly, it remains unknown whether secretory carcinomas harbor genomic hallmarks of other breast cancers, especially basal-like and/or triple negative tumors, to suggest a genetic relatedness.
Recent studies have identified mammary analog secretory carcinomas at other sites, including major and minor salivary glands, thyroid and skin, which show similar morphologic and immunophenotypic features to secretory carcinomas of the breast and also harbor ETV6-NTRK3 fusions. [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] Indeed, a number of salivary-like tumors may arise in the breast, suggesting a histogenetic relationship of these tumors irrespective of the site of origin. These include acinic cell carcinomas, mucoepidermoid carcinomas, and adenoid cystic carcinomas, among other even rarer tumors. [45] [46] [47] [48] [49] [50] [51] Accordingly, special breast cancer subtypes may be more closely related to their respective counterparts at other sites than to other primary breast carcinomas, but supportive genetic data are sparse and may be tumordependent. A recent study suggested that adenoid cystic carcinomas arising in the breast lack TP53 and PIK3CA mutations typical of other basal-like breast cancers and share a variety of mutated pathways with salivary gland adenoid cystic carcinomas, including but not limited to the characteristic MYB-NFIB gene fusion, suggesting that the breast tumors are more similar to their salivary gland counterparts than they are to other breast cancers. 45 The genetic data do not address the discordance in clinical behavior between the tumors. On the other hand, acinic cell carcinomas of the breast harbor hallmark genetic alterations of other typical triple negative breast carcinomas, including frequent TP53 mutations and complex patterns of copy number alterations, not present in salivary gland acinic cell carcinomas, suggesting that the two tumors are not related despite histologic similarity. 52, 53 Given the lack of genomic data or comparative genetic studies, the relatedness of secretory carcinomas of the breast to analog tumors arising in other sites remains unknown.
In this study, we used capture-based next-generation sequencing of 510 cancer-related genes to more comprehensively characterize the genomics of breast secretory carcinomas and to compare the genetics of these rare tumors with those of mammary analog secretory carcinomas and with published data of other breast cancers, including triple negative and/or basal tumors. The findings shed light on our understanding of secretory carcinoma biology and may help explain the favorable clinical behavior of these tumors.
Materials and methods

Study Population
This study was approved by the institutional review boards of the University of California San Francisco, Kaiser Permanente and Weill Cornell. Nine breast secretory carcinomas and six mammary analog secretory carcinomas of the salivary gland were identified in the consultation services and Pathology department archives of our respective institutions, spanning years 2006 to 2015 (SC1-9 and MASC1-6, respectively). All the specimens were fixed in 10% neutral buffered formalin and embedded in paraffin. Clinical information was obtained from the electronic medical records of our respective institutions and/or from the referring facilities.
Capture-Based Next-Generation DNA Sequencing
Matched normal and tumor tissues were selected from the nine breast secretory carcinomas and six salivary gland mammary analog secretory carcinomas for capture-based next-generation DNA sequencing. Sequencing was performed at the UCSF Clinical Cancer Genomics Laboratory, using an assay that targets the coding regions of 510 cancer-related genes, select introns from 42 genes, and TERT promoter with a total sequencing footprint of 2.8 Mb (UCSF500 panel; Supplementary Table S1 ). Sequencing libraries were prepared from genomic DNA extracted from both tumor and normal formalin-fixed paraffin-embedded tissue. For one breast secretory carcinoma, DNA from associated ductal carcinoma in situ was extracted and analyzed separately. Target enrichment was performed by hybrid capture using a custom oligonucleotide library. Sequencing was performed on an Illumina HiSeq 2500. Duplicate sequencing reads were removed computationally to allow for accurate allele frequency determination and copy number calling. The analysis was based on the human reference sequence UCSC build hg19 (NCBI build 37), using the following software packages: BWA: 0.7.13, Samtools: 1.1 (using htslib 1.1), [54] [55] [56] [57] [58] [59] [60] [61] [62] [63] [64] Only insertions/deletions up to 100 base pairs in length were included in the mutational analysis. Somatic single-nucleotide variants and insertions/deletions were visualized and verified using Integrated Genome Viewer. Genome-wide copy number analysis based on on-target and off-target reads was performed by CNVkit and Nexus Copy Number (Biodiscovery, Hawthorne, CA, USA). 60 Large-scale chromosomal changes were defined as those involving entire chromosomes or chromosome arms.
Targeted RNA Sequencing
Targeted RNA sequencing was performed on one mammary analog secretory carcinoma without an identified fusion gene by DNA sequencing (MASC5). RNA was isolated from 5 micron thick unstained formalin-fixed paraffin-embedded tumor sections on glass slides using Qiagen RNeasy kit according to the manufacturer's instructions (Qiagen, Germantown, MD, USA). Complementary DNA was subsequently prepared using NEBNext Ultra II DNA Library Prep Kit for Illumina according the manufacturer's instructions (New England Biolabs, Ipswich, MA, USA). Sequencing and analysis was performed using the UCSF500 platform as described above.
Fluorescence In Situ Hybridization
For ETV6 fluorescence in situ hybridization, 5 micron thick unstained formalin-fixed paraffinembedded sections on glass slides were baked at 60°C for 1 h, rinsed in 100% ethanol, then pretreated with 0.2 N HCl (20 min, room temperature), followed by 1 M NaSCN (30 min, 80°C) before protease digestion with pepsin (2.5 mg/ml pepsin for 27 min at 37°C). The slides were then fixed in 10% phosphate-buffered saline-buffered formalin, rinsed, dehydrated in an ethanol series, and air dried. The slides were hybridized overnight at 37°C with an equimolar mixture of Vysis LSI ETV6 (Tel) SpectrumOrange and (Cen) SpectrumGreen DNA probes (07J77-003 and 07J77-004, respectively; Abbott Molecular, Des Plaines, IL, USA) after denaturing for 5 min at 80°C. The slides were washed to remove unbound probes and counterstained with 4,6 diamidino-2-phenylidole. Enumeration of the fusion and break-apart signals was conducted using a Zeiss fluorescence microscope.
Tissue Microarray Construction
Tissue microarrays were created from ER-/PR-/ HER2-(n = 111), ER+/HER2-(n = 32), and HER2+ (n = 30) untreated breast cancers diagnosed at UCSF from 1997 to 2009. 65 All the specimens were fixed in 10% buffered formalin and embedded in paraffin. Three 1 mm punch biopsy tissue cores were obtained from each tumor to create triplicates for analysis. Only tumors with at least two evaluable cores with tumor tissue were used for analysis.
Immunohistochemistry
Immunohistochemistry was performed on whole tissue sections (all antibodies) or tissue microarrays (MUC4 and SOX10). The following antibodies were used: S100 (polyclonal, 1:2000, DAKO, Carpinteria, CA, USA), SOX10 (EP268, 1:250, Cell Marque, Rocklin, CA, USA), MUC4 (8G7, 1:500, Millipore, Billerica, MA, USA), GATA3 (L50-823, 1:50, Biocare Medical, Concord, CA, USA), mammaglobin (304-1A5, 1:4, DAKO), gross cystic disease fluid protein 15 (GCDFP-15; 23A3, undiluted, Covance, Dedham, MA, USA), CK5/6 (D5/16B4, 1:200 with anti-background, Millipore), and EGFR (5B7, undiluted, Roche, Ventana Medical Systems, Tucson, AZ, USA). Antigen retrieval was as follows: for S100-none; for SOX10-Bond epitope retrieval solution 2 (Leica Biosystems, Buffalo Grove, IL, USA); for MUC4-Bond epitope retrieval solution 1 (Leica Biosystems); for GATA3-Bond epitope retrieval solution 2 (Leica Biosystems); for mammaglobin and GCDFP-15-Bond epitope retrieval solution 1 (Leica Biosystems); for CK5/6-Bond epitope retrieval solution 1 (Leica Biosystems); and for EGFR, CC1 (Roche, Ventana Medical Systems). For a subset of secretory carcinomas received in consultation, immunohistochemistry for some markers was performed at the referring institution.
For estrogen receptor, progesterone receptor, and HER2, positive staining was defined according to ASCO/CAP guidelines. 66, 67 For all other markers, positive expression was defined as any cytoplasmic (MUC4, mammaglobin, GCDFP-15, CK5/6), nuclear (SOX10, GATA3), combined cytoplasmic/nuclear (S100), or combined membranous/cytoplasmic (EGFR) staining. Percentages of tumor cells stained by each antibody were recorded, with diffuse staining defined as 480% of tumor cell staining. For invasive ductal carcinomas with 480% of MUC4 tumor cell staining in all evaluable cores on tissue microarrays, whole tissue sections were subsequently stained.
Results
Clinicopathologic Features of Secretory Carcinomas
Clinicopathologic features of the breast secretory carcinomas analyzed in this study are shown in Table 1 Table 1 ). Associated carcinoma in situ was present in six (67%) cases. Four (50%) tumors arose in the subareolar region, and two (25%) were present in axillary ectopic breast tissue (n = 8). One tumor (SC4) arising in the axilla also demonstrated tumor cells with prominent apocrine cytologic features (eosinophilic cytoplasmic granules and rounded nuclei with prominent nucleoli) in many areas, intimately admixed with tumor cells showing characteristic secretory features (Figure 1 ). Two patients (SC1 and SC2) presented with single, small ipsilateral axillary lymph node metastases. Clinical follow-up was available for five patients, none of which showed recurrences or death due to breast cancer (mean follow-up interval 78 months, range 45-98 months; Table 1 ).
Salivary gland mammary analog secretory carcinomas demonstrated similar cytologic and architectural features as the breast tumors ( Figure 1 and Table 1 ). Five (83%) tumors arose in the parotid gland and one (17%) arose in a minor buccal salivary gland. No patients showed recurrences, and all are alive without evidence of disease (mean follow-up interval 29 months, range 9-47 months; Table 1 ).
Immunohistochemical Profiles of Secretory Carcinomas
Breast secretory carcinomas and mammary analog secretory carcinomas showed similar immunophenotypes (Table 2) . Five (56%) breast secretory carcinomas were triple negative, and all four ER-positive tumors showed weak to moderate expression in only ~2 to 15% of tumor cells. As expected, all breast (n = 7) and salivary gland (n = 6) carcinomas expressed S100 protein and mammaglobin, with diffuse expression identified in most tumors. In addition, diffuse and strong MUC4 expression was identified in all 15 secretory carcinomas regardless of site, and SOX10 was positive in all nine breast and five out of six salivary gland tumors ( Figure 2 and All secretory carcinomas expressed cytokeratin CK5/6 (n = 8 breast, n = 5 salivary gland) and/or EGFR (n = 5 breast, n = 5 salivary gland), consistent with a basal-like immunophenotype previously reported for breast secretory carcinomas 1, 17 (Table 2 and Figure 2 ). EGFR tended to be positive in a higher proportion of tumor cells than CK5/6, which was only focally expressed (≤5% of tumor cells) in five out of eight (63%) breast and three out of five (60%) salivary gland tumors. In contrast, EGFR was expressed in ≥ 20% of tumor cells in three out of five (60%) breast and all five (100%) salivary gland tumors ( Figure 2 and Table 2 ). All tumors that were stained for both markers showed positivity for either CK5/6 or EGFR in ≥ 10% of tumor cells ( Table 2) .
Genomics of Breast Secretory Carcinomas with Comparison to Salivary Gland Mammary Analog Secretory Carcinomas
All tested breast (n = 9) and salivary gland analog (n = 5) secretory carcinomas were positive for ETV6 SC1  0  0  0  100  90  90  95  100  5  1  20  SC2  0  0  0  100  100  100  90  100  30  80  70  SC3  0  0  0  60  30  100  100  100  1  1  50  SC4  2  o 1  0  80  90  90  20  100  70  5  ND  SC5  5  0  0  100  50  95  0  100  5  10  2  SC6  5  0  0  95  100  100  30  100  2  20  1  SC7  0  0  0  90  80  90  90  100  30  5  ND  SC8  15  15  0  ND  90  100  ND  ND  ND  ND  ND  SC9  0  0  0  ND  100  95  20 ND ND 1 ND % SC +ive (n) 44 (9) 11 (9) 0 (9) 100 (7) 100 (9) 100 (9) 88 (8) 100 (7) 100 (7) 100 (8) gene rearrangement by break-apart fluorescence in situ hybridization probe, including the associated carcinoma in situ component of one breast secretory carcinoma case (SC5; Figure 3 ). The mean target coverage of next-generation DNA sequencing was 459 unique reads per target interval for breast secretory carcinomas (range 154-880) and 512 for salivary gland mammary analog secretory carcinomas (range 317-699; Table 3 and Supplementary Table S2 ). All nine breast secretory carcinomas (n = 9) and five of six salivary gland mammary analog secretory carcinomas revealed ETV6-NTRK3 gene fusions by DNA sequencing (Figure 3) . In all cases, the DNA breakpoints were in intron 5 of ETV6 (NM_001987) and intron 14 of NTRK3, (NM_0010 12338), resulting in a predicted fusion gene composed of N-terminal exons 1-5 of ETV6, which encompass the sterile alpha motif (SAM) dimerization domain, and C-terminal exons 15-20 of NTRK3, which includes the protein kinase domain (Figure 3b ). 9 One salivary gland tumor (MASC5) did not demonstrate an ETV6-NTRK3 gene fusion by DNA sequencing, despite a mean sequencing coverage of 536 reads per interval in this case. Subsequent targeted RNA sequencing of MASC5 did reveal the same ETV6-NTRK3 fusion (exons 1-5 of ETV6 fused to Figure 3b) ; thus, the ETV6 breakpoint in this case likely occurred in a small region of ETV6 intron 5 that is poorly covered in all of the samples. In one out of nine breast and two of six salivary gland tumors, the rearrangements were complex and involved additional genes ( Figure 3 and Table 3 ), whereas balanced reciprocal t(12;15)(p13;q25) translocations were identified in six out of nine breast and three of six salivary gland tumors ( Figure 3 and Table 3 ). This translocation results in a derivative chromosome 15, which contains the oncogenic fusion. Two of the cases with reciprocal fusions (SC3 and MASC2) demonstrated duplication of the oncogenic derivative chromosome (Figure 3a and d) . Both cases demonstrated copy gain of the distal portion of chromosome 12p extending from intron 5 of ETV6 gene to the telomere (Figure 4c,  Supplementary Figure S1 ), which correlates with gain of the 5′ ETV6 FISH probe (orange signal, Figure 3d ). In MASC2, the distal 12p gain is accompanied by a copy gain in 15q extending from intron 14 of NTRK3 to the centromere (Figure 4c, Supplementary  Figure S1 ), which is the expected result if the oncogenic derivative chromosome is duplicated. In SC3, the distal 12p gain is accompanied by a copy loss in 15q from intron 14 of NTRK3 to the telomere (Figure 4c and Supplementary Figure S1) , which is the expected result if the oncogenic derivative chromosome is duplicated and the normal copy of chromosome 15 is lost.
The mutational burden over the 2.8 megabase footprint of the panel was very low in both groups, and there were from 0 to 2 nonsynonymous coding mutations per tumor and averaging 0.7 and 0.8 variants per breast and salivary gland tumor, respectively (Table 3 and Figure 3) . No mutations were identified in genes frequently mutated in breast cancers, including basal carcinomas. 22, [25] [26] [27] [28] [29] Indeed, no known pathogenic mutations were identified in any of the cancer-related genes on the panel, nor were recurrently mutated genes found. The few identified variants of unknown significance are shown in Table 3 . Four of the breast (44%) and two of the salivary gland (33%) carcinomas did not harbor any somatic coding mutations, including one of the breast tumors with lymph node metastasis (SC2; Table 3 ).
Copy number analysis revealed simple genomes without any chromosomal gains or losses in five (56%) breast secretory carcinomas and two (33%) mammary analog secretory carcinomas. In one additional salivary gland tumor, the only copy number change was duplication of the rearranged derivative chromosome 15 with ETV6-NTRK3 gene fusion (MASC2; Table 3, Figure 3 and Supplementary Figure S1 ). The remainder of the tumors in both the groups showed only very few copy number changes, ranging from 1 to 2 gains or losses per tumor. The average number of copy number changes per tumor was 1.3 (0.9 in breast secretory carcinomas and 2 in salivary gland analog secretory carcinomas). Recurrent gains included distal chromosome 12p (part of the rearranged oncogenic derivative chromosome harboring ETV6-NTRK3) in SC3 and MASC2, chromosome 8q (two breast tumors) and chromosome 16 (two breast and one salivary gland tumor); chromosome 22 was lost in two salivary gland tumors. None of the tumors showed 1q gain or 16q loss characteristic of the low-grade neoplasia pathway in the breast. 68 No focal amplifications or deep deletions were identified (Table 3 and Figure 4 ).
Discussion
This is the first study to analyze the genomics of secretory carcinomas using next-generation sequencing of a large panel of cancer-related genes. In summary, we have shown that secretory carcinomas of the breast and mammary analog secretory carcinomas of the salivary gland have overlapping immunoprofiles, simple genomes with no or few copy number alterations, a very low mutation burden and lack of additional known pathogenic genetic aberrations in 510 common cancer genes aside from ETV6-NTRK3 fusion genes. The findings suggest that, despite a basal-like immunophenotype, secretory carcinomas of the breast do not harbor genomic alterations typical of basal-like carcinomas of no special type and are genetically more similar to mammary analog secretory carcinomas of the salivary gland than they are to other primary breast cancers.
ETV6-NTRK3, initially described in congenital fibrosarcoma, has been identified in tumors of various lineages, including cellular mesoblastic nephroma, acute myeloid leukemia, breast secretory carcinoma, and secretory analog carcinomas of various sites, most frequently of the salivary glands. 1, 9, 34, 40, 42, 43, [69] [70] [71] [72] [73] [74] [75] [76] The rearrangement fuses the N-terminal dimerization domain of ETV6 with the C-terminal tyrosine kinase domain of NTRK3, producing a chimeric tyrosine kinase with transforming activity that is activated upon oligomerization. 9, 77, 78 By RNA analysis, the most frequent fusion breakpoints are between exon 5 of ETV6 and exon 15 of NTRK3, although variant fusions involving the first four exons of ETV6 and/or exon 14 of NTRK3 have been described in mammary analog secretory carcinomas and radiation-induced thyroid carcinomas. 9, 43, 44, 71 Putative alternate ETV6 rearrangements involving unidentified partners have also been described in the salivary gland and have been suggested to demonstrate more aggressive histologic features. 43, 79 All breast and salivary gland secretory carcinomas in our study harbored predicted classic ETV6-NTRK3 fusions between ETV6 exon 5 and NTRK3 exon 15.
If alternate fusions exist in breast secretory carcinomas, they are likely to be exceedingly rare. One breast and one salivary gland tumor in our series each showed duplication of the entire rearranged chromosome harboring ETV6-NTRK3, and similar findings have been previously reported in breast secretory carcinomas. Of 20 total breast secretory carcinomas in our study and two prior reports, 1,32 duplicated chromosomes harboring ETV6-NTRK3 were identified in 20% of the tumors, in addition to the duplication present in one of the mammary analog secretory carcinomas in our study. Given the apparent frequency of the duplication, it is likely that increased copies of ETV6-NTRK3 are selected for and provide additional advantage to the The copy number profile of MASC2 (bottom) shows copy gain of distal 12p from the ETV6 breakpoint to the telomere (black arrow), as well as copy gain of 15q from the NTRK3 breakpoint and extending proximally to the centromere (red arrow). The findings are indicative of duplication of the derivative chromosome harboring the ETV6-NTRK3 fusion, which is the only copy number alteration in this tumor. The copy number profile of SC3 (top) also shows copy gain of distal 12p from the ETV6 breakpoint to the telomere (black arrow), which in this case is associated with copy neutral 15q from the centromere to the NTRK3 breakpoint and copy loss of distal 15q from the NTRK3 breakpoint to the telomere (red arrow). The findings are consistent with duplication of the derivative chromosome harboring the ETV6-NTRK3 fusion plus loss of normal chromosome 15, which is also supported by allelic imbalance of copy neutral proximal 15q by singlenucleotide polymorphism analysis and fluorescence in situ hybridization (not shown here; see also text and Supplementary Figure S1 ). Red arrows represent large-scale (chromosome or chromosome arm level) copy number alterations private to only one tumor.
tumor cells beyond that conferred by the fusion gene alone. ETV6-NTRK3 transforms multiple cell lineages, and expression causes secretory carcinogenesis in mouse models, but whether the fusion gene is the sole driver or requires additional alterations for tumorigenesis is unclear. 9, 11, 12, 16, 77 In this study, we did not identify any additional recurrent alterations using our panel of 510 cancer genes; however, it remains possible that either our panel size or cohort size were too small to detect additional recurrent alterations. Additional sequencing studies of larger numbers of these rare tumors are required to determine whether ETV6-NTRK3 gene fusion is the only driving alteration in secretory carcinoma development or growth.
Although breast secretory carcinomas have a basal-like immunoprofile, their genomics and relationship to other triple negative basal carcinomas of no special type remained unknown before our study. We have shown that secretory carcinomas have a very low mutation burden without pathogenic mutations in genes frequently mutated in basal carcinomas, such as TP53 among others. Furthermore, these tumors have very simple genomes with no or few copy number changes, also in stark contrast to most basal carcinomas of no special type. 21 The findings highlight the heterogeneity of basal-like cancers and the importance of histopathology in diagnosis. Identification of a true basal molecular phenotype using gene expression profiling may be useful to determine whether the immunohistochemical profile is a reliable surrogate for basal-like specification in these tumors. 80 The absence of chromosomal copy number changes typical of the low-grade neoplasia pathway (such as 1q gain and 16q loss) also further distinguishes these low-grade tumors from breast cancers in the lowgrade neoplasia pathway. 81 We speculate that the simple genomic profiles of secretory carcinomas may well help explain their favorable clinical course, which is in stark contrast to most other basal breast cancers. Of note, we found no evidence of more aggressive genomic features in breast secretory carcinomas that presented with axillary lymph node metastasis compared with those that did not. This may help explain the notion that even locally metastatic breast secretory carcinomas have favorable outcomes with high long-term survival. 4, 8 Unfortunately, insufficient metastatic tumor tissue was available to separately analyze the genomics of the metastases for possible genomic progression. Given our relatively small sample size, additional studies of larger cohorts and of metastatic secretory carcinomas may be instructive.
Our results suggest that breast secretory carcinomas are more closely related to their salivary gland counterparts than they are to other breast cancers. The immunoprofiles of secretory carcinomas and mammary analog secretory carcinomas are nearly identical. In addition to S100 protein, mammaglobin, and Stat5a, 17, 20, 36, 39, 42, 82, 83 we show that the breast tumors express MUC4 and SOX10, previously described in their salivary gland counterparts, 42, 82, 84 and suggest that these markers may provide an additional diagnostic tool useful in the differential diagnosis to trigger genetic testing. Conversely, mammary analog secretory carcinomas, like the breast tumors, frequently express EGFR and CK5/6 in addition to previously described markers. 1, 17, 42, 82 By DNA sequencing, we found no measurable differences in the genomics of secretory carcinomas of either breast or salivary gland. In conjunction with recent studies of adenoid cystic carcinomas of the breast, 45 the findings indicate that the rare fusion gene-driven special breast carcinoma subtypes genetically resemble their counterparts at other sites rather than other breast cancers, and that the classification of tumor type is site independent.
